AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 145 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 1.31 and the average weighting 1.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,089,022 | +128.4% | 118,020 | +54.9% | 0.00% | – |
| Q1 2024 | $2,228,146 | +24.9% | 76,202 | -4.9% | 0.00% | – |
| Q4 2023 | $1,783,582 | -64.8% | 80,089 | -60.8% | 0.00% | -100.0% |
| Q3 2023 | $5,060,039 | +136.0% | 204,446 | +170.1% | 0.00% | 0.0% |
| Q2 2023 | $2,143,767 | +29.6% | 75,698 | +5.2% | 0.00% | – |
| Q1 2023 | $1,653,542 | -32.8% | 71,987 | -17.8% | 0.00% | -100.0% |
| Q4 2022 | $2,460,005 | +17.1% | 87,607 | +17.9% | 0.00% | 0.0% |
| Q3 2022 | $2,101,000 | +20.1% | 74,278 | -5.9% | 0.00% | 0.0% |
| Q2 2022 | $1,749,000 | -21.6% | 78,919 | +3.0% | 0.00% | 0.0% |
| Q1 2022 | $2,232,000 | +105.0% | 76,637 | +131.3% | 0.00% | – |
| Q4 2021 | $1,089,000 | -37.6% | 33,133 | -12.4% | 0.00% | – |
| Q3 2021 | $1,745,000 | -13.4% | 37,824 | +3.5% | 0.00% | – |
| Q2 2021 | $2,014,000 | -5.4% | 36,542 | -11.3% | 0.00% | -100.0% |
| Q1 2021 | $2,128,000 | +23.4% | 41,191 | +3.5% | 0.00% | 0.0% |
| Q4 2020 | $1,725,000 | +88.5% | 39,804 | +52.2% | 0.00% | – |
| Q3 2020 | $915,000 | -98.6% | 26,144 | -97.9% | 0.00% | -100.0% |
| Q2 2020 | $66,488,000 | +53.7% | 1,243,239 | +2.0% | 0.02% | +33.3% |
| Q1 2020 | $43,252,000 | -35.4% | 1,219,051 | -13.1% | 0.02% | -14.3% |
| Q4 2019 | $66,997,000 | +57.8% | 1,403,072 | +7.0% | 0.02% | +90.9% |
| Q3 2019 | $42,469,000 | -39.0% | 1,310,779 | -6.2% | 0.01% | -38.9% |
| Q2 2019 | $69,671,000 | +23.0% | 1,396,773 | +66.3% | 0.02% | -5.3% |
| Q1 2019 | $56,646,000 | +46.0% | 839,948 | -0.2% | 0.02% | +26.7% |
| Q4 2018 | $38,809,000 | -39.1% | 841,654 | +1.9% | 0.02% | -25.0% |
| Q3 2018 | $63,682,000 | -8.8% | 825,746 | -0.4% | 0.02% | -13.0% |
| Q2 2018 | $69,820,000 | +1.8% | 828,926 | -1.2% | 0.02% | -11.5% |
| Q1 2018 | $68,585,000 | +41.5% | 838,654 | -1.1% | 0.03% | +52.9% |
| Q4 2017 | $48,474,000 | -26.3% | 847,894 | -14.0% | 0.02% | -29.2% |
| Q3 2017 | $65,810,000 | +29.0% | 985,932 | -0.6% | 0.02% | +50.0% |
| Q2 2017 | $51,025,000 | +172.2% | 991,733 | +208.9% | 0.02% | +166.7% |
| Q1 2017 | $18,748,000 | +385.1% | 321,030 | +246.6% | 0.01% | +500.0% |
| Q4 2016 | $3,865,000 | +454.5% | 92,622 | +601.8% | 0.00% | – |
| Q3 2016 | $697,000 | +42.5% | 13,198 | +13.1% | 0.00% | – |
| Q2 2016 | $489,000 | +34.0% | 11,669 | +29.7% | 0.00% | – |
| Q1 2016 | $365,000 | -5.2% | 8,994 | +51.7% | 0.00% | – |
| Q4 2015 | $385,000 | +2.4% | 5,929 | +11.4% | 0.00% | – |
| Q3 2015 | $376,000 | -30.4% | 5,324 | +9.5% | 0.00% | – |
| Q2 2015 | $540,000 | -50.5% | 4,861 | -50.0% | 0.00% | – |
| Q4 2014 | $1,090,000 | – | 9,727 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |